GLP-1 Hair Loss: How Common It Is and Will It Grow Back

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. The information provided should not be used for diagnosing or treating a health condition. Always consult your healthcare provider before starting, stopping, or changing any medication or treatment plan. Individual results may vary.

Yes, hair loss is a listed side effect of GLP-1 weight-loss medications. In the clinical trials behind the labels, it was reported by 4–5% of people on Zepbound and 3% on Wegovy 2.4 mg, compared with 1% on placebo, and both labels say it was "associated with weight reduction."

The usual pattern is diffuse shedding that starts a few months after rapid weight loss begins. Dermatologists call this telogen effluvium. It is typically temporary, and hair tends to return to its normal fullness within six to nine months once the trigger settles. Patchy bald spots, an itchy or inflamed scalp, or shedding that keeps going are different, and they need a doctor to look.

How to Stop Hair Loss on GLP-1 Medications (Doctor's Advice) — Dr. Spencer Nadolsky

How common is hair loss on GLP-1s? The label numbers

From the current US prescribing information for each drug:

Drug	Hair loss on the drug	Placebo	Where in the label
Zepbound (tirzepatide)	5% at 5 mg · 4% at 10 mg · 5% at 15 mg	1%	Table 1 (weight-reduction Studies 1 and 2)
Wegovy (semaglutide) 2.4 mg	3%	1%	Table 3 (adult weight-reduction trials)
Wegovy (semaglutide) 7.2 mg	6% (vs 3% on 2.4 mg)	1%	Table 4
Mounjaro (tirzepatide)	Not listed in the label's common adverse reactions table	—	Alopecia listed under postmarketing reports (6.2)
Ozempic (semaglutide)	Not listed in the label's common adverse reactions table	—	Alopecia listed under postmarketing reports (6.2)

The Rybelsus and Saxenda labels also list alopecia among postmarketing reports. Postmarketing reports come from people using the drug after approval, so the labels say a frequency cannot be reliably estimated.

Women report it far more often than men

Both weight-management labels break hair loss down by sex:

Zepbound: 7.1% of women vs 0.5% of men on the drug (placebo: 1.3% of women, 0% of men). No Zepbound-treated patient stopped the drug because of hair loss.
Wegovy 2.4 mg: 4% of women vs 0.9% of men (placebo: 2% of women, 0 men).
Wegovy 7.2 mg trials: 8.4% of women vs 0.2% of men. In that group, 1 event led to stopping treatment and 5 led to a dose reduction.

A 2026 systematic review notes that women in GLP-1 trials tend to lose more weight than men, which may be part of the explanation. The reason is not settled. More detail per drug is on the Zepbound side effects and Wegovy side effects pages.

Why does GLP-1 hair loss happen?

The leading explanation is telogen effluvium: a stress on the body pushes more hairs than usual into the resting phase at once, and they fall out together some weeks later. The American Academy of Dermatology (AAD) lists losing 20 pounds or more as one of the triggers, alongside childbirth, surgery and high fever. The AAD says dermatologists believe GLP-1 hair loss is caused by the sudden weight loss.

Other contributors are thought to play a part:

Eating much less. A 2026 systematic review (Gupta et al.) describes how substantial calorie restriction and rapid fat loss can bring on telogen effluvium through short-term shortfalls in iron, zinc, protein or other nutrients. The authors suggest that low energy intake, rather than the weight loss itself, may be the trigger.
A direct drug effect is possible but unproven. The AAD says GLP-1 drugs "may also have a direct effect" on hair, and that researchers need more information to say for sure.

What a large cohort study found

A 2026 study of US health records (Vidal et al., JAAD International) compared about 548,000 matched adults, GLP-1 users and people who never took one. At 12 months, GLP-1 users had higher odds of telogen effluvium (adjusted odds ratio 1.76), of pattern hair loss (1.64) and of nonscarring hair loss overall (1.40). There was no significant link with alopecia areata, the autoimmune, patchy form. This kind of study shows an association, not cause and effect.

When does it start, and does hair grow back on its own?

Onset: the Gupta review puts shedding at roughly 2–3 months after starting treatment. The AAD says most people notice the shedding "a few months after" the trigger. So hair loss often shows up after the fastest weight loss, not on day one.
How long it lasts: acute telogen effluvium lasts less than six months. Shedding that continues past six months is called chronic, and the review links it to ongoing triggers such as eating too little for a long time.
Regrowth: the AAD says hair tends to regain its normal fullness within six to nine months. The Gupta review reports improvement generally within 3–6 months after weight stabilizes. The review also says there is no strong evidence that GLP-1s permanently damage hair follicles.

How to stop hair loss on a GLP-1: what helps

Nothing reliably stops telogen effluvium once it starts. These steps target the triggers the evidence points to:

Make protein the anchor of each small meal. Protein is one of the nutrients the review links to shedding. When appetite is low, eat the protein part of the plate first. The protein calculator gives a daily starting number, and protein shakes can fill the gap on low-appetite days.
Do not let intake drop to almost nothing. The review names severe calorie restriction as a trigger and recommends avoiding dramatic weight loss. If you are eating very little most days, tell your prescriber or a dietitian.
Include iron- and zinc-rich foods. The review lists iron and zinc with protein as nutrients to keep up. Meat, poultry, fish, eggs, beans and lentils are everyday sources.
Ask about a blood test before buying hair supplements. The review suggests checking a blood count, ferritin (iron stores), thyroid and vitamin D when shedding persists. The AAD article quotes a dermatologist who suggests a standard daily multivitamin; ask your prescriber or dietitian whether that fits you.
Raise it with your prescriber. The review says slower weight loss may help people prone to shedding. How fast to increase your dose is a decision for your prescriber. Never skip, delay or change a dose on your own.

Fast weight loss can also change how your face looks; see how to prevent "Ozempic face" for the same protein-first approach, and muscle loss on GLP-1s for the overlap with strength training.

When to see your doctor or a dermatologist

Book an appointment with your prescriber or a dermatologist if:

You see patchy bald spots, a receding hairline or a widening part rather than all-over shedding.
Your scalp itches, burns, hurts or looks inflamed, or you see scaling or redness. The Gupta review lists scalp itch or inflammation as a sign of possible scarring hair loss, which needs a dermatologist.
Shedding continues past 6–9 months, or gets worse instead of better.
Hair loss comes with other new symptoms, such as unusual tiredness. The Gupta review suggests blood tests (blood count, ferritin, thyroid, vitamin D) to rule out other causes. See also fatigue on GLP-1s.
You are eating very little or vomiting often. Severe or ongoing vomiting can lead to dehydration, which the GLP-1 labels warn can affect the kidneys.

The AAD says the sooner treatment begins for true hair loss, the better the outlook. Shedding is common and usually temporary, but it is still worth a visit if you are worried.

What to track (and why it helps)

Shedding starts months after its trigger, so memory is a poor guide. Log "hair loss" from the side-effect catalog in the GLP-1 symptom tracker with a severity from 1 to 10. Log your weight on the same days. A record that shows "shedding started about 10 weeks after my fastest month of weight loss" helps your prescriber or dermatologist tell telogen effluvium from other causes.

Meal logs show whether protein dropped during low-appetite weeks. Before an appointment, export the doctor report PDF and share it yourself; it covers your medication history, weight, nutrition and side effects over time. The doctor visit prep guide lists what else to bring. Other symptoms are on the GLP-1 side effects hub.

GLP-1 Hair Loss FAQ

Does hair grow back after GLP-1 hair loss?

In most cases, yes. The usual pattern, telogen effluvium, is temporary. The American Academy of Dermatology says hair tends to regain its normal fullness within six to nine months, and a 2026 systematic review found no strong evidence that GLP-1s permanently damage hair follicles. Patchy loss or shedding that lasts beyond 6–9 months should be checked by a dermatologist.

Does tirzepatide cause hair loss?

The Zepbound (tirzepatide) label lists hair loss in 5% of people at 5 mg, 4% at 10 mg and 5% at 15 mg, compared with 1% on placebo, and says it was associated with weight reduction. It was reported in 7.1% of women and 0.5% of men. The Mounjaro label does not list it in its common adverse reactions table but includes alopecia among postmarketing reports.

Does Ozempic or Wegovy cause hair loss?

The Wegovy label lists hair loss in 3% of adults on 2.4 mg and 6% on 7.2 mg, compared with 1% on placebo. The Ozempic label does not list it in its common adverse reactions table, but alopecia appears in its postmarketing reports. Both drugs contain semaglutide.

How do I stop hair loss on a GLP-1?

No step reliably stops shedding once it starts, but you can target the likely triggers: build each small meal around protein, avoid eating too little, include iron- and zinc-rich foods, and ask your prescriber about a blood test before buying supplements. How fast your dose goes up is your prescriber's decision. Never change a dose on your own.

When does GLP-1 hair loss start?

Telogen effluvium usually shows up a few months after its trigger. A 2026 systematic review puts it at roughly 2–3 months after starting a GLP-1, which is often after the fastest weight loss. Shedding that starts right away or comes in patches is a reason to see a doctor.

Sources verified 2026-10-26

Zepbound prescribing information (revised 08/2026): Table 1 hair loss (placebo 1%; 5 mg 5%; 10 mg 4%; 15 mg 5%); section 6.1 "Hair Loss" (7.1% female vs 0.5% male; placebo 1.3% vs 0%; no Zepbound discontinuations).
Wegovy prescribing information (revised 06/2026): Table 3 (2.4 mg 3% vs placebo 1%); Table 4 (7.2 mg 6%, 2.4 mg 3%, placebo 1%); section 6.1 "Hair Loss" (sex breakdown, discontinuations and dose reductions).
Mounjaro prescribing information (revised 08/2026): Table 1 (hair loss not listed); 6.2 postmarketing, alopecia.
Ozempic prescribing information (revised 05/2026): Table 1 (hair loss not listed); 6.2 postmarketing, alopecia. Also Rybelsus and Saxenda 6.2 postmarketing, alopecia.
American Academy of Dermatology: How can GLP-1 drugs affect my skin, hair, and nails? (updated 2/17/2026)
American Academy of Dermatology: Do you have hair loss or hair shedding?
Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: a systematic review of current evidence and implications for counseling. Sci Prog. 2026;109(2). doi:10.1177/00368504261444578
Vidal SI, Akiska YM, Nasseri M, et al. Increased risk of hair loss with GLP-1 receptor agonists: a real-world multicenter TriNetX cohort study. JAAD Int. 2026;25:133–135. doi:10.1016/j.jdin.2026.01.014

GLP AI

Editorial

Educational content from the GLP AI team about living on a GLP-1. Clinical review is credited by name on pages a reviewer has checked. Not medical advice.